Top entities: Regeneron Pharmaceuticals, Pomerantz LLP, Nasdaq.

What category does this event fall under?

Regulatory — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Regeneron Pharmaceuticals disclosed trial failure · Pomerantz LLP investigates claims Regeneron Pharmaceuticals

Is this event still developing?

This is an active story, last updated Jul 24, 2026. Coverage continues to evolve.

Regulatory class action

Regeneron class action lawsuit

Q: When did this event occur?

First reported Jul 21, 2026; last updated Jul 24, 2026.

Q: What is the market impact?

General. The class action lawsuit and the underlying trial failures have negatively impacted Regeneron's stock price, with cumulative losses exceeding 15%.

Analysis based on 6 articles · First reported Jul 21, 2026 · Last updated Jul 24, 2026

Sentiment

-30

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The class action lawsuit and the underlying trial failures have negatively impacted Regeneron's stock price, with cumulative losses exceeding 15%. The legal proceedings may lead to financial penalties or settlements, further affecting investor sentiment.

Pharmaceuticals

Event Summary

A class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. by Pomerantz LLP, alleging securities fraud or other unlawful business practices. The lawsuit stems from disclosures made by Regeneron on April 29, 2026, during its first quarter earnings call, that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients eligible for analysis of progression-free survival. Subsequently, on May 15, 2026, Regeneron announced that the Phase 3 trial of Fianlimab did not reach statistical significance for the primary endpoint. These disclosures caused Regeneron's stock price to decline significantly, falling 6.21% on April 29 and 9.82% on May 16. Investors who purchased Regeneron securities during the class period have until September 14, 2026, to seek appointment as lead plaintiff.

Key Actions

90 Regeneron Pharmaceuticals disclosed trial failure

70 Pomerantz LLP investigates claims Regeneron Pharmaceuticals

Entities Involved

stock

Regeneron Pharmaceuticals

Regeneron is the defendant in the class action lawsuit, facing allegations of securities fraud. The company's stock price dropped significantly after disclosing trial alterations and failure, and the lawsuit adds legal and reputational risk.

Importance 100.0 Sentiment -40.0

priv

Pomerantz LLP

Pomerantz LLP is the law firm filing the class action lawsuit against Regeneron. The firm is representing investors and stands to gain legal fees if the case is successful.

Importance 30.0 Sentiment 0.0

exch

Nasdaq

Nasdaq is the exchange where Regeneron's stock is listed. The event does not directly affect Nasdaq, but the stock price movements are recorded on the exchange.

Importance 10.0 Sentiment 0.0

Relationships

Pomerantz LLP related ↔ Nasdaq

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard